At 007 Venture Partners, we seek out companies solving critical problems with technology that changes the model — not just the output. Digistain is doing exactly that in one of the most important fields of all: cancer diagnostics.
From an immigrant background, Dr. Hemmel Amrania worked in construction during university to fund his education—an early sign of the grit and resilience that defines his journey.
Now a PhD physicist and founder, Hemmel is known for his ability to hack complex systems to make them smarter and faster. He’s applying that same mindset to revolutionise cancer diagnostics with AI, bringing faster, fairer care to millions.
Not Just a Better Test — A Better Diagnostic Model
Digistain’s core insight is simple but profound: to make personalised cancer care accessible at scale, we need more than incremental improvements. We need a new diagnostic paradigm.
Traditional genomic tests look “upstream,” analysing DNA to estimate a tumour’s risk profile. Digistain turns that model on its head — using proteomic analysis to observe what the tumour is actually doing. This “downstream” approach captures behaviour, not just potential, and leads to dramatically better treatment decisions.
A Structural Advantage on Cost and Speed
Digistain’s technology is not only more accurate — it’s also faster and cheaper. Their patented chemical-free process enables fully digital testing. That means:
- No expensive reagents
- No centralised labs
- No delays in logistics
The result: a significantly lower cost and a faster turnaround time than incumbent diagnostic models can deliver. In low-resource settings and overstretched health systems alike, this matters deeply.
A Platform Built to Scale
What makes Digistain particularly exciting to us is that this is not a one-product company. The underlying platform is capable of rapidly developing new biomarkers for other cancers — and validating them efficiently.
In short, Digistain is building a new category of diagnostic infrastructure — one that will compound in value as more cancers are addressed and more geographies come online.
Why We Invested
Digistain represents the kind of rare opportunity we are always on the lookout for:
- A world-class team with deep domain expertise
- Clinically proven and commercially validated technology
- Early regulatory approvals secured
- Revenue already being generated
The company is now at a commercial inflection point, poised to scale globally — and improve outcomes for millions of cancer patients along the way.
We’re proud to back Digistain, and to partner with founders building a fairer, faster, and smarter healthcare future.
